RO115804B1
(ro)
*
|
1992-12-11 |
2000-06-30 |
Merck & Co Inc |
Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
|
US5492920A
(en)
*
|
1993-12-10 |
1996-02-20 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5494919A
(en)
*
|
1993-11-09 |
1996-02-27 |
Merck & Co., Inc. |
2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
US5492916A
(en)
*
|
1993-12-23 |
1996-02-20 |
Merck & Co., Inc. |
Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
CA2176140A1
(en)
*
|
1993-11-24 |
1995-06-01 |
Meng Hsin Chen |
Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
|
US5721251A
(en)
*
|
1993-12-10 |
1998-02-24 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5721250A
(en)
*
|
1993-12-23 |
1998-02-24 |
Merck & Co. Inc. |
Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
US5783582A
(en)
*
|
1994-07-20 |
1998-07-21 |
Merck & Co., Inc. |
Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
|
US5656606A
(en)
*
|
1995-02-17 |
1997-08-12 |
Merck & Co., Inc. |
Camphor compounds promote release of growth hormone
|
US5731317A
(en)
*
|
1995-03-10 |
1998-03-24 |
Merck & Co., Inc. |
Bridged piperidines promote release of growth hormone
|
US5559128A
(en)
*
|
1995-04-18 |
1996-09-24 |
Merck & Co., Inc. |
3-substituted piperidines promote release of growth hormone
|
US5616571A
(en)
*
|
1995-06-06 |
1997-04-01 |
Merck & Co., Inc. |
Bisphosphonates prevent bone loss associated with immunosuppressive therapy
|
AU7169696A
(en)
*
|
1995-09-26 |
1997-04-17 |
Merck & Co., Inc. |
3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
|
US5767124A
(en)
*
|
1995-10-27 |
1998-06-16 |
Merck & Co., Inc. |
Polymorphic forms of a growth hormone secretagogue
|
US6028196A
(en)
*
|
1995-10-27 |
2000-02-22 |
Merck & Co., Inc. |
Process for the preparation of a growth hormone secretagogue
|
EA199800337A1
(ru)
*
|
1995-10-27 |
1998-10-29 |
Мерк Энд Ко., Инк. |
Способ получения гормона роста, усиливающего секрецию
|
JPH11513989A
(ja)
*
|
1995-10-27 |
1999-11-30 |
メルク エンド カンパニー インコーポレーテッド |
成長ホルモン分泌促進薬の湿式造粒製剤
|
WO1997022004A1
(en)
|
1995-12-13 |
1997-06-19 |
Merck & Co., Inc. |
Assays for growth hormone secretagogue receptors
|
US6531314B1
(en)
|
1996-12-10 |
2003-03-11 |
Merck & Co., Inc. |
Growth hormone secretagogue receptor family
|
GB2308362A
(en)
*
|
1995-12-19 |
1997-06-25 |
Lilly Industries Ltd |
Pharmaceutical indole derivatives
|
WO1997022367A1
(en)
*
|
1995-12-20 |
1997-06-26 |
Merck & Co., Inc. |
Radiolabeled growth hormone secretagogue
|
GB9601724D0
(en)
*
|
1996-01-29 |
1996-03-27 |
Merck Sharp & Dohme |
Therapeutic agents
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
GB9612276D0
(en)
*
|
1996-06-12 |
1996-08-14 |
Merck & Co Inc |
4-Spiroindoline piperidines promote release of growth hormone
|
WO1997034604A1
(en)
*
|
1996-03-21 |
1997-09-25 |
Merck & Co., Inc. |
4-spiroindoline piperidines promote release of growth hormone
|
US5804578A
(en)
*
|
1996-04-03 |
1998-09-08 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
CA2253390A1
(en)
*
|
1996-05-07 |
1997-11-13 |
Merck & Co., Inc. |
Enhancement of sleep with a growth hormone secretagogue
|
WO1997041878A1
(en)
*
|
1996-05-07 |
1997-11-13 |
Merck & Co., Inc. |
Treatment of mood disorders with a growth hormone secretagogue
|
AU4342097A
(en)
*
|
1996-09-13 |
1998-04-02 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
|
US5877182A
(en)
*
|
1996-09-13 |
1999-03-02 |
Merck & Co., Inc. |
Piperidines promote release of growth hormone
|
US6046333A
(en)
*
|
1996-10-25 |
2000-04-04 |
Merck & Co., Inc. |
Convergent process for the preparation of a growth hormone secretagogue
|
EP0941115A1
(en)
*
|
1996-11-05 |
1999-09-15 |
Novo Nordisk A/S |
Use of growth hormone or a growth hormone secretagogue for promoting bone formation
|
AU5594398A
(en)
*
|
1996-12-09 |
1998-07-03 |
Merck & Co., Inc. |
Methods and compositions for preventing and treating bone loss
|
WO1998025605A1
(en)
*
|
1996-12-13 |
1998-06-18 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
US5962462A
(en)
*
|
1996-12-13 |
1999-10-05 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
UA59384C2
(uk)
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
AU7105498A
(en)
*
|
1997-04-14 |
1998-11-11 |
Merck & Co., Inc. |
Combination therapy for the prevention and treatment of osteoporosis
|
GB2324726A
(en)
*
|
1997-05-01 |
1998-11-04 |
Merck & Co Inc |
Combination Therapy for the Treatment of Osteoporosis
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
US6117880A
(en)
*
|
1997-10-30 |
2000-09-12 |
Merck & Co., Inc. |
Somatostatin agonists
|
US6013652A
(en)
*
|
1997-12-04 |
2000-01-11 |
Merck & Co., Inc. |
Spiro-substituted azacycles as neurokinin antagonists
|
WO1999036431A1
(en)
|
1998-01-16 |
1999-07-22 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
US6294534B1
(en)
|
1998-06-11 |
2001-09-25 |
Merck & Co., Inc. |
Spiropiperidine derivatives as melanocortin receptor agonists
|
JP2002517444A
(ja)
*
|
1998-06-11 |
2002-06-18 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
|
US6682908B1
(en)
|
1998-07-10 |
2004-01-27 |
Merck & Co., Inc. |
Mouse growth hormone secretagogue receptor
|
WO2000002919A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
WO2000009538A2
(en)
|
1998-08-10 |
2000-02-24 |
Merck & Co., Inc. |
Canine growth hormone secretagogue receptor
|
US6639076B1
(en)
*
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6194402B1
(en)
|
1998-09-02 |
2001-02-27 |
Merck & Co., Inc. |
Enhancement of return to independent living status with a growth hormone secretagogue
|
US6380184B1
(en)
|
1998-10-28 |
2002-04-30 |
Bristol-Myers Squibb Co. |
Benzoazepines and analogs thereof useful as growth hormone secretagogues
|
KR100699404B1
(ko)
|
1999-02-18 |
2007-03-23 |
가켄 세야쿠 가부시키가이샤 |
성장 호르몬 분비촉진제로서의 신규 아미드 유도체
|
US6828331B1
(en)
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6541634B2
(en)
|
1999-02-26 |
2003-04-01 |
Pfizer Inc. |
Process for preparing growth hormone secretagogues
|
US6518292B1
(en)
*
|
1999-03-12 |
2003-02-11 |
Bristol-Myers Squibb Co. |
Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
|
US6525203B1
(en)
|
1999-03-12 |
2003-02-25 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
EP1187614A4
(en)
|
1999-06-04 |
2005-06-22 |
Merck & Co Inc |
SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
|
US20040266802A1
(en)
*
|
1999-06-07 |
2004-12-30 |
Alain Calvet |
Tricyclic analgesics
|
WO2001004119A1
(en)
*
|
1999-07-13 |
2001-01-18 |
Merck & Co., Inc. |
Amido spiropiperidines promote the release of growth hormone
|
EP1256575B1
(en)
*
|
2000-02-18 |
2005-08-17 |
Meiji Seika Kaisha Ltd. |
Phenoxyalkylamine derivatives useful as opioid delta receptor agonists
|
AU4928101A
(en)
|
2000-03-23 |
2001-10-03 |
Merck & Co Inc |
Spiropiperidine derivatives as melanocortin receptor agonists
|
EP1268449A4
(en)
|
2000-03-23 |
2004-09-15 |
Merck & Co Inc |
SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
|
DE60115227T2
(de)
|
2000-05-11 |
2006-08-24 |
Bristol-Myers Squibb Co. |
Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
|
EP1159964B1
(en)
|
2000-05-31 |
2009-10-28 |
Pfizer Products Inc. |
Use of growth hormone secretagogues for stimulating gastrointestinal motility
|
WO2002015909A1
(en)
|
2000-08-23 |
2002-02-28 |
Merck & Co., Inc. |
Substituted piperidines as melanocortin receptor agonists
|
AP1699A
(en)
*
|
2001-03-21 |
2006-12-26 |
Warner Lambert Co |
New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
|
DK1385514T5
(da)
|
2001-04-18 |
2009-03-09 |
Euro Celtique Sa |
Spiroinden- og spiroindanforbindelser
|
US6911447B2
(en)
*
|
2001-04-25 |
2005-06-28 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
WO2002094825A1
(fr)
*
|
2001-05-22 |
2002-11-28 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de spiropiperidine
|
US7125840B2
(en)
*
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
AU2002357692A1
(en)
|
2001-11-09 |
2003-05-26 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
WO2003087069A2
(en)
*
|
2002-04-09 |
2003-10-23 |
Eli Lilly And Company |
Dipeptidic growth hormone secretagogues
|
US20060167268A1
(en)
*
|
2002-04-09 |
2006-07-27 |
Eli Lilly And Company, Patent Division, |
Growth hormone secretagogues
|
US20040010010A1
(en)
*
|
2002-04-30 |
2004-01-15 |
Ebetino Frank Hallock |
Melanocortin receptor ligands
|
US7026335B2
(en)
*
|
2002-04-30 |
2006-04-11 |
The Procter & Gamble Co. |
Melanocortin receptor ligands
|
GB0213715D0
(en)
*
|
2002-06-14 |
2002-07-24 |
Syngenta Ltd |
Chemical compounds
|
TW200504033A
(en)
*
|
2002-10-23 |
2005-02-01 |
Procter & Gamble |
Melanocortin receptor ligands
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
CN1297557C
(zh)
*
|
2003-04-10 |
2007-01-31 |
上海药明康德新药开发有限公司 |
螺环类模板化合物的制备
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
WO2005027913A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
|
EP1684786A4
(en)
*
|
2003-10-24 |
2007-12-12 |
Merck & Co Inc |
IMPROVING THE HORMONAL LEVEL OF GROWTH
|
US7504506B2
(en)
|
2003-11-04 |
2009-03-17 |
Elixir Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
GB0328906D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
GB0328908D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
US20050261332A1
(en)
*
|
2004-04-02 |
2005-11-24 |
Distefano Peter |
Sulfonamides and uses thereof
|
UA87854C2
(xx)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
|
EP2389941A1
(en)
|
2004-08-18 |
2011-11-30 |
Elixir Pharmaceuticals, Inc. |
Growth-hormone secretagogues
|
EP2374455A3
(en)
|
2004-08-19 |
2012-03-28 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
US7547790B2
(en)
*
|
2004-10-28 |
2009-06-16 |
Sankyo Company, Limited |
Optically active 4,4-di-substituted oxazolidine derivative and method for producing same
|
RU2007124373A
(ru)
*
|
2004-11-29 |
2009-01-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы мускариновых рецептеров
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
US7858635B2
(en)
*
|
2005-12-22 |
2010-12-28 |
Vertex Pharmaceuticals Incorporated |
Spiro compounds as modulators of muscarinic receptors
|
RU2008137583A
(ru)
*
|
2006-02-22 |
2010-03-27 |
Вертекс Фармасьютикалз Инкорпорейшн (Us) |
Спиропиперидины в качестве модуляторов мускариновых рецепторов
|
EP1988892A2
(en)
|
2006-02-22 |
2008-11-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
CN101092396B
(zh)
*
|
2006-06-20 |
2010-09-15 |
上海药明康德新药开发有限公司 |
螺[1,3-二氢茚-4'-哌啶-1-羧酸]模板化合物的制备方法
|
AU2007269863A1
(en)
*
|
2006-06-29 |
2008-01-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CA2660903A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CN101573121A
(zh)
*
|
2006-08-18 |
2009-11-04 |
弗特克斯药品有限公司 |
毒蕈碱受体调节剂
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
JP5271917B2
(ja)
*
|
2007-01-12 |
2013-08-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
スピロクロマノン誘導体
|
EP2118080B1
(en)
|
2007-02-09 |
2016-08-31 |
Ocera Therapeutics, Inc. |
Macrocyclic ghrelin receptor modulators and methods of using the same
|
WO2008134828A2
(en)
|
2007-05-04 |
2008-11-13 |
Katholieke Universiteit Leuven |
Tissue degeneration protection
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2009045519A1
(en)
*
|
2007-10-03 |
2009-04-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
WO2009061676A2
(en)
*
|
2007-11-06 |
2009-05-14 |
Amira Pharmaceuticals, Inc. |
Antagonists of pgd2 receptors
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2350010B1
(en)
|
2008-10-30 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
US8927503B2
(en)
|
2010-07-28 |
2015-01-06 |
The University Of Queensland |
Modulations of protease activated receptors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8546416B2
(en)
|
2011-05-27 |
2013-10-01 |
Novartis Ag |
3-spirocyclic piperidine derivatives as ghrelin receptor agonists
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
US9868763B2
(en)
|
2011-11-07 |
2018-01-16 |
The University Of Queensland |
Modulators of protease activated receptors
|
WO2013190520A2
(en)
|
2012-06-22 |
2013-12-27 |
The General Hospital Corporation |
Gh-releasing agents in the treatment of vascular stenosis and associated conditions
|
WO2014065341A1
(ja)
|
2012-10-24 |
2014-05-01 |
第一三共株式会社 |
筋萎縮性側索硬化症治療剤
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
AU2014331812B2
(en)
|
2013-10-09 |
2019-01-17 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
EP3134408B1
(en)
|
2014-04-22 |
2020-08-12 |
Merck Sharp & Dohme Corp. |
FACTOR XIa INHIBITORS
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
WO2017075535A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
RU2020103730A
(ru)
*
|
2017-06-30 |
2021-07-30 |
Квиксджен, Инк. |
Новые спиролактоновые соединения
|
RU2020130837A
(ru)
|
2018-02-21 |
2022-03-21 |
ЭйАй ТЕРАПЬЮТИКС, ИНК. |
Комбинационная терапия апилимодом и глутаматергическими агентами
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
WO2022040070A1
(en)
|
2020-08-18 |
2022-02-24 |
Merck Sharp & Dohme Corp. |
Bicycloheptane pyrrolidine orexin receptor agonists
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|